Sarepta Therapeutics,, Inc. - SRPT STOCK NEWS

Sarepta Therapeutics (NASDAQ:SRPT) announced that its senior management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 12:30 p.m. E.T. The event will be held at the Sheraton New York and will be webcast live on Sarepta's investor relations website. This presentation highlights Sarepta's commitment to developing precision genetic medicine for rare diseases, focusing on Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs) with over 40 programs in development.

Sarepta Therapeutics (NASDAQ: SRPT) announced the FDA has lifted the clinical hold on its investigational treatment SRP-5051 (vesleteplirsen) for Duchenne muscular dystrophy. This move follows a serious adverse event and allows the company to resume dosing in the U.S. after modifying the trial protocol to enhance monitoring for hypomagnesemia. Global enrollment in the MOMENTUM trial continues, with expectations to complete by the end of 2022. SRP-5051 utilizes advanced PPMO technology, targeting exon 51 of the dystrophin gene, and shows promise for improved efficacy and dosing frequency.

Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to 29 employees, as previously approved by the Compensation Committee. The awards, totaling 22,900 stock options and 11,750 restricted stock units (RSUs), were made as inducements for employment. The options have an exercise price of $109.38, equal to the stock's closing price on the grant date, August 31, 2022. Both options and RSUs will vest over four years, contingent on continued employment. This initiative reflects Sarepta's continued commitment to attract top talent in the precision genetic medicine sector.

Sarepta Therapeutics (NASDAQ:SRPT) reported Q2 2022 total revenues of $233.5 million, a 49% increase year-over-year, with net product revenues reaching $211.2 million. The company raised its full-year revenue guidance to $905-$920 million and net product revenue to $825-$840 million. Sarepta plans to submit a Biologics License Application for its gene therapy SRP-9001 this fall, which aims to treat Duchenne muscular dystrophy. Despite these positives, the net loss for Q2 stood at $231.5 million, compared to a loss of $81.4 million in Q2 2021.

Sarepta Therapeutics (NASDAQ:SRPT) has granted equity awards to 28 newly hired individuals, approved by its Board's Compensation Committee as part of its 2014 Employment Commencement Incentive Plan. This includes options to purchase 36,100 shares at an exercise price of $92.95, matching the market close on July 29, 2022. Vesting occurs over four years, contingent on continued employment. Sarepta focuses on precision genetic medicine for rare diseases, holding a leading position in therapies for Duchenne muscular dystrophy and limb-girdle muscular dystrophies, with over 40 development programs.

Sarepta Therapeutics (NASDAQ: SRPT) announced plans to submit a Biologics License Application (BLA) for its investigational gene therapy SRP-9001 aimed at treating Duchenne muscular dystrophy. This submission is slated for fall 2022, following positive feedback from regulatory discussions. SRP-9001 has previously received Fast Track, Rare Pediatric Disease, and Orphan Drug designations. The therapy aims to deliver components of dystrophin to muscle tissue, enhancing the quality of life for affected patients.

Sarepta Therapeutics (NASDAQ:SRPT) will announce its second quarter 2022 financial results on August 2, 2022, after market close. A conference call to discuss these results and provide a corporate update will follow at 4:30 p.m. E.T. The event will be available via live webcast on Sarepta's investor relations website. Sarepta is a leader in precision genetic medicine, focusing on rare diseases, with over 40 programs in development, particularly for Duchenne muscular dystrophy and limb-girdle muscular dystrophies.

Sarepta Therapeutics and Roche presented new findings at the ICNMD, showing that SRP-9001 exhibits significant functional benefits for Duchenne muscular dystrophy patients. In a study with 20 participants, SRP-9001-treated individuals improved by 4 points on the NSAA at 52 weeks, with p-values demonstrating strong statistical significance (p<0.0001). Additionally, long-term data revealed no decline in function among older patients, showcasing a 7-point increase above baseline. The safety profile remains consistent across over 80 patients treated, reinforcing confidence in the ongoing Phase 3 EMBARK study.

Sarepta Therapeutics (NASDAQ:SRPT) will host a webcast on July 6, 2022, to present new functional data from the clinical trials of SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy (DMD). The company will share an integrated analysis of one-year data across three studies (101, 102, and 103) involving participants who received the target dose of SRP-9001, comparing results to an external control group. The event will be accessible via their investor relations website.